Inhibitors: resolving diagnostic and therapeutic dilemmas.
about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitorsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitorsEfficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.FEIBA safety profile in multiple modes of clinical and home-therapy application.Immune tolerance therapy in patients with acquired hemophilia.Therapy for haemophilia: recent advances and goals for the future.Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.Optimal haemophilia care versus the reality.New approaches in the management of inhibitor patients.Laboratory issues in bleeding disorders.Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.Genetic engineering for haemophilia A.The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.International workshop on immune tolerance induction: consensus recommendations.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.Haemophilia A: meeting the needs of individual patients.High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.Novel drugs to treat hemophilia.Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.Factor VIII therapy for hemophilia A: current and future issues.The role of Rixubis™ in the treatment of hemophilia B.When is enough…enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors.Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.A close insight to factor VIII inhibitor in the congenital hemophilia A.Innovating immune tolerance induction for haemophilia.Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.Health-related quality of life in haemophilia patients with inhibitors and their caregivers.Identification and characterization of an adenine to guanine transition within intron 10 of the factor VIII gene as a causative mutation in a patient with mild haemophilia A.Late immune tolerance induction in haemophilia A patients.Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain.Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.Inhibitors, what is the risk of treatment intensity?
P2860
Q24187069-AF3834F6-0E1C-43D1-96A6-F09593A5E309Q24236388-1DEA1660-500A-46EF-A9D7-E62A8C78B8EDQ24247217-B228A243-1FFD-457E-8ADB-202CE71DA663Q31098999-E164F15A-4122-41ED-BC03-83F223D3282EQ33361533-E2C7FF3E-67F3-4255-BCC5-265338AC30ABQ34541550-6300B2E7-07CB-4645-9340-38964E504E78Q35895862-C682CDBA-848A-4977-8391-B6DC26BD6086Q35994817-5C895B66-3F8A-4116-87F0-9DF9C6664652Q36066048-3B849F2D-1DC7-4983-9ED0-3C8403575CEDQ36230842-7C2C0287-4181-4D71-8B3C-DE137EFA6629Q36291064-34882BEF-E7A7-42DA-87ED-808CC1B5B28AQ36399847-C9ADB733-FC57-4A04-A6DA-3E5AAC5520EBQ36426640-83EEC3F1-633A-4A87-837D-C3A2DDB7A0DFQ36473056-286C66FB-2879-4D97-9D05-CC84588FB2B6Q36536149-5298B8C2-CBFF-493F-AEBA-79F533919DC4Q36600245-4FEB1A97-4724-407C-A6B6-C23F003981AAQ36643861-3B576595-1BDF-42DF-855E-8CB9D4F1D208Q36861097-35666F20-2852-4A78-A8EF-A19AB85D683DQ36981731-C51D634C-9DBB-4A68-B4E8-32C59230B59EQ37008132-DF57AD75-02F0-42A8-BFEB-F5DD6F2C5BA4Q37355230-38602A55-1793-4917-9DD7-7E2AE7D03831Q37775029-64B09D56-0E31-4DEF-8CEC-2D6A348D498DQ37778291-59F5FBB1-3309-4A9A-A79C-1F6A20C4AC21Q37924970-51DDAC9F-E342-48AD-B8D6-EC059DDA28A1Q38203350-EE8FFD07-EC59-471B-81E9-4046B9971481Q38210808-8CB068B0-811A-421D-919C-F7E173CDACF8Q38221821-2D45D5C3-761B-445E-9053-7D21351D6E7EQ38547840-DF9C4D3D-4B06-4DA0-9097-5ADF420990C9Q38883211-C0DC46F8-5CEF-46CF-9F0E-DEF6835D3A6CQ38894155-98336144-13C7-4F49-8AA2-0695F140EEB0Q41580780-7C4FABA5-87C2-4F8B-B501-1B1265BA4A53Q42776949-61768036-08C7-42CF-81DC-3CB1B933E167Q44648378-235C7311-EDFF-40F5-B755-04597A3AE347Q44846549-F45FF520-9A56-4880-822B-86CC076911CCQ44853253-80A506CA-9E3A-4FEB-8A4B-F974C2EEC7C6Q44988735-A757FC66-B7C8-4EAA-AC74-5C371555522FQ45859514-E0B694CA-A43D-4760-BEE5-2F924C0122A5Q45863828-DF2D660E-28DA-4A98-A3A7-A0C7A4ABE20CQ45864945-BD9DA74F-43A4-48C8-B837-6FE784D091CAQ45867446-62D1FDDF-FE59-4A5B-969C-D7998FBF1072
P2860
Inhibitors: resolving diagnostic and therapeutic dilemmas.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@ast
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@en
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@nl
type
label
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@ast
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@en
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@nl
prefLabel
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@ast
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@en
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@nl
P2860
P1433
P1476
Inhibitors: resolving diagnostic and therapeutic dilemmas.
@en
P2093
Dimichele D
P2860
P304
P356
10.1046/J.1365-2516.2002.00626.X
P577
2002-05-01T00:00:00Z